FindTrial
Sign In

Perioperative anti-thrombotic strategy in patients with gynecological malignant tumor after percutaneous coronary intervention

Perioperative anti-thrombotic strategy in patients with gynecological malignant tumor after percutaneous coronary intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100675
Enrollment
Unknown
Registered
2025-04-14
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombosis and gynecological tumors

Interventions

Monoclonal antibody group (aspirin or clopidogrel):None
Bispecific antibody group (clopidogrel aspirin):None

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients receiving PCI treatment in Anzhen Hospital for 1 year between January 2025 and December 2026 who underwent surgery for gynecological malignant tumors were included.

Exclusion criteria

Exclusion criteria: Procedures that occurred within the first two weeks after PCI were excluded. Exclude operational treatment and bedside intervention. Patients who stopped aspirin or P2Y12 inhibitors at doctor's orders or on their own more than two weeks before the date of gynecological surgery were excluded.

Design outcomes

Primary

MeasureTime frame
Coagulation factor function ;—

Countries

China

Contacts

Public ContactXinlei Zhang

Beijing Anzhen Hospital, Capital Medical University

13911183913@163.com+86 139 1118 3913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026